186466-64-8

Basic information

• Product Name: Carbamic acid, [(1R)-2-hydroxy-1,2-dimethylpropyl]-, 1,1-dimethylethyl ester
• Synonyms: Carbamic acid, [(1R)-2-hydroxy-1,2-dimethylpropyl]-, 1,1-dimethylethyl ester;(R)-tert-butyl 3-hydroxy-3-methylbutan-2-ylcarbamate
• CAS NO: 186466-64-8
• Molecular Formula: C₁₀H₂₁NO₃
• Molecular Weight: 203.27864
• Product Categories: N-BOC
• Mol File: 186466-64-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Carbamic acid, [(1R)-2-hydroxy-1,2-dimethylpropyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1R)-2-hydroxy-1,2-dimethylpropyl]-, 1,1-dimethylethyl ester(186466-64-8)
• EPA Substance Registry System: Carbamic acid, [(1R)-2-hydroxy-1,2-dimethylpropyl]-, 1,1-dimethylethyl ester(186466-64-8)

Safety Data

• Hazardous Substances Data: 186466-64-8(Hazardous Substances Data)

Upstream product

• 91103-47-8 N-(tert-butoxycarbonyl)-D-alanine methyl ester 
• 74-88-4 methyl iodide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 917-54-4 methyllithium 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 1610360-94-5 (R)-N-(3-hydroxy-3-methylbutan-2-yl)-2-nitrobenzenesulfonamide 
• 1610360-88-7 (R)-2,2,3-trimethyl-1-((2-nitrophenyl)sulfonyl)aziridine 
• 600733-91-3 (3R)-3-amino-2-methylbutan-2-ol 
• 1610361-04-0 (R)-N-(3-methyl-3-phenoxybutan-2-yl)-2-nitrobenzenesulfonamide 
• 1428631-14-4 (R)-5-((3-fluorophenyl)ethynyl)-N-(3-methoxy-3-methylbutan-2-yl)picolinamide 
• 1428631-05-3 (R)-N-(3-hydroxy-3-methylbutan-2-yl)-5-(p-tolylethynyl)picolinamide 
• 1428631-09-7 (R)-N-(3-hydroxy-3-methylbutan-2-yl)-5-(m-tolylethynyl)picolinamide 
• 1428631-02-0 (R)-N-(3-hydroxy-3-methylbutan-2-yl)-5-(o-tolylethynyl)picolinamide 
• 1428631-07-5 (R)-5-((2,4-difluorophenyl)ethynyl)-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide 
• 1428631-00-8 (R)-5-((3,5-difluorophenyl)ethynyl)-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide 
• 1428631-08-6 (R)-5-((4-fluorophenyl)ethynyl)-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide 
• 1428631-06-4 (R)-5-((2-fluorophenyl)ethynyl)-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide 
• 1428631-11-1 (R)-N-(3-hydroxy-3-methylbutan-2-yl)-5-(phenylethynyl)picolinamide 
• 1428630-85-6 (R)-5-((3-fluorophenyl)ethynyl)-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide 

Relevant articles and documents

N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS

Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N-1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing (or inhibiting) cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

NOVEL MEDICINE COMPOSED OF BENZIMIDAZOLE COMPOUND

PROBLEM TO BE SOLVED: To provide an agent for treating or preventing a disease associated with SCN9A(Nav1.7). SOLUTION: The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. [R1a, R1b, R1c, R1d: H, halogen, cyano, C1-4 alkyl, C1-4 alkoxy or the like. R2, R3: H, C1-6 alkyl, C3-10 cycloalkyl or the like. R4: H, C1-6 alkyl, C3-7 cycloalkyl or the like. m: 1, 2 or 3. L: CR7R8(R7, R8: H, OH, C1-4 alkyl, C1-4 alkoxy or the like)]. SELECTED DRAWING: None COPYRIGHT: (C)2019,JPOandINPIT

NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF

The present invention provides a medicament for treating a disease involving Nav 1.7 such as neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, and multiple sclerosis, which comprises a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c and R1d are hydrogen, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, or the like, provided that at least one of R1a, R1b, R1c and R1d is C6-10 aryl, C6-10 aryloxy, or the like, R2 and R3 are hydrogen, C1-6 alkyl, C3-10 cycloalkyl, or the like, R4 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, or the like, m is 1, 2 or 3, L is CR7R8, and R7 and R8 are hydrogen, hydroxyl, C1-4 alkyl, C1-4 alkoxy, or the like.

Possible reason for the unusual regioselectivity in nucleophilic ring opening of trisubstituted aziridines under mildly basic conditions

2,2,3-Trisubstituted aziridines are known to undergo ring opening at the more substituted carbon under mildly basic conditions. However, the reason for the formation of the more sterically encumbered product has never been examined. Several trisubstituted aziridines, with different substitution patterns at the C-2 and C-3 carbons, were synthesized to change the electronics of the aziridine ring system. These changes had no effect on the regioselectivity of the ring-opening reaction. Using the B3LYP/6-31G* DFT basis set it was determined that the transition state for opening at the more substituted carbon proceeds at a lower energy than the transition state at the less substituted carbon.

PYRROLOPYRAZINE KINASE INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

3-amido pyrrolopyrazine JAK kinase inhibitors: Development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models

The Janus kinases (JAKs) are involved in multiple signaling networks relevant to inflammatory diseases, and inhibition of one or more members of this class may modulate disease activity or progression. We optimized a new inhibitor scaffold, 3-amido-5-cycl

Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): Discovery of 5-((3-fluorophenyl)ethynyl)- N -(3-methyloxetan-3-yl)picolinamide (ML254)

Positive allosteric modulators (PAMs) of metabotropic glutamate receptor 5 (mGlu5) represent a promising therapeutic strategy for the treatment of schizophrenia. Both allosteric agonism and high glutamate fold-shift have been implicated in the neurotoxic profile of some mGlu5 PAMs; however, these hypotheses remain to be adequately addressed. To develop tool compounds to probe these hypotheses, the structure-activity relationship of allosteric agonism was examined within an acetylenic series of mGlu5 PAMs exhibiting allosteric agonism in addition to positive allosteric modulation (ago-PAMs). PAM 38t, a low glutamate fold-shift allosteric ligand (maximum fold-shift ～3.0), was selected as a potent PAM with no agonism in the in vitro system used for compound characterization and in two native electrophysiological systems using rat hippocampal slices. PAM 38t (ML254) will be useful to probe the relative contribution of cooperativity and allosteric agonism to the adverse effect liability and neurotoxicity associated with this class of mGlu5 PAMs.

PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula (I), wherein the variables Q and R, R2, and R3 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Asymmetric alkylations using SuperQuat auxiliaries - An investigation into the synthesis and stability of enolates derived from 5,5-disubstituted oxazolidin-2-ones

Studies on the alkylation of enolates derived from a range of N-acyl-5,5-dimethyloxazolidin-2-ones and N-acyl-5,5-diphenyloxazolidin-2-ones reveal that high yields and high diastereoselectivities are best obtained when homochiral 4-isopropyl-5,5-dimethyloxazolidin-2-one is employed as a chiral auxiliary.